Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Fresenius Endorses PEAK Campaign Efforts To Reduce Dialysis Patient Mortality
Fresenius Medical Care, which operates the nation"s leading network of dialysis clinics, today endorsed the Performance Excellence and Accountability in Kidney Care (PEAK) campaign recently launched by Kidney Care Partners (KCP) - a coalition of patient advocates, dialysis professionals, care providers and manufacturers working together to improve quality of care for individuals with chronic kidney disease (CKD). The PEAK initiative is designed to significantly reduce the mortality rate for patients in their first year of dialysis.

Unique Cardiovascular Treatment Readied For Global Market: Proprietary Paccocath(R) Technology Is The Only Drug Eluting Balloon With Clinical Data
MEDRAD Interventional(TM)/Possis(R) announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial Disease (PAD). These milestones include the selection of physician investigators for U.S. clinical trials and the completion of a new state-of-the-art manufacturing facility.
News of the day
UPMC Surgeon Performs 2,000th Prostate Cancer Surgery In Pittsburgh
Joel B. Nelson, M.D., chairman of the University of Pittsburgh Medical Center"s (UPMC) Department of Urology, performed his 2,000th radical prostatectomy at UPMC Shadyside, a milestone achieved by only a handful of surgeons worldwide. Radical prostatectomy, or removal of the entire prostate gland, is the most common treatment for patients with localized prostate cancer. Studies show that recovery from prostate cancer is significantly associated with a surgeon"s lifetime experience performing this operation.
Public Health

First Viable Treatment Option For Highly Resistant Form Of CML May Be Provided By ChemGenex's Omacetaxine

ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation. Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center, a lead investigator in the study, presented the data. Dr. Cortes said, "It appears that omacetaxine was well tolerated in this study and durable hematological and cytogenetic responses were observed in some CML patients with the T315I mutation." He added that "Several novel drugs have already been investigated in this difficult-to-treat population, but they have not had a reasonable risk:benefit ratio. These results suggest that omacetaxine may represent the first viable treatment option for this population of patients who currently have no established treatment options." Data were presented from 66 patients: 40 in chronic phase, 16 in accelerated phase and 10 in blast phase. Highlights of the data were: * Chronic phase patients Complete hematologic response (CHR) rate of 85% with a median response duration 8.9 months Major cytogenetic response (MCyR) rate of 15% with a median response duration 6.1 months Accelerated phase patients CHR rate of 31% with a median duration 4.1 months MCyR rate of 6% with a median response duration 1.8 months Blast phase patients CHR rate of 20% with a median duration 3.3 months Tolerability Investigators reported that omacetaxine is generally well tolerated, and that the most common side effect is reversible and transient myelosuppression. Commenting on the presentation, Dr. Greg Collier, Chief Executive Officer and Managing Director of ChemGenex, said, "This is a very important milestone in the development of omacetaxine and in the evolution of ChemGenex. The data presented today will be provided to the FDA in the final part of our rolling NDA submission; this project remains on target for completion in Q3 this year." Dr. Collier finished by expressing his deep appreciation for patients and investigators who participated in this important trial. Dr. Collier and ChemGenex"s Chief Medical Officer Dr. Adam Craig will host an investor conference call and webcast to discuss the clinical results from both ASCO and the EHA Congress on Thursday 11th of June at 10 am AEST. Omacetaxine Overview Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, specifically binding to the ribosomal A-site cleft and inhibiting protein translation of short-lived oncoproteins that are upregulated in leukemic cells (particularly Cyclin-D1, Mcl-1 and c-Myc). As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously. Joan Kureczka Kureczka/Martin Associates


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009